Product Name: EphB2 (777-783) pY780
Product Number: PE-04ALZ95
Size: 200 µg      Price:47.00
1 mg      $US94.00
5 mg      206.00
Peptide Name: EphB2 (777-783) pY780

Product Use: Services as a blocking peptide for use with the EphB2-pY780 rabbit polyclonal antibody (Cat. No.: AB-PK610) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. This is the major in vivo phosphorylation site in EphA2. Y780 phosphorylation is predicted to be stimulatory for phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: DPT-pY-TSA

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1007 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: EphB2 - pY780 phosphosite-specific antibody (Cat. No.: AB-PK610)

Scientific Background: EphB2 is a protein-tyrosine kinase of the TK group and Eph family. It is a receptor kinase, and is activated by binding ephrin-B1, B2, or B3. Eph and Eph receptors are associated with nervous system development events, and lead to contact-dependent signalling through adjacent cells. Eph receptors are widely expressed in early development and rarely detected in adult tissues. EphB2 signalling has an important role in the development and structural organization of neurons. EphB2 is also involved in angiogenesis, palate development and inner ear development through endolymph production. EphB2 appears to be a tumour suppressor protein (TSP). The active form of the protein kinase normally acts to inhibit tumour cell proliferation. EphB2 mutations have been found in prostate cancer. Most prostate cancers are adenocarcinomas that derived from acini of the prostatic ducts. K1019X mutation was significantly more common in African American probands. Over-expression of EphB2 has been frequently detected in both well-differentiated adenocarcinomas (10 of 13) and poorly differentiated adenocarcinomas (9 of 14). EphB2 expression restricts the invasiveness of colorectal cancer cells into ephrin-B1 expressing cell populations, thus segregating cancer cells from normal cells.